title: Do valsartan and losartan have the same effects in the treatment of coronary artery disease?
abstract: BACKGROUND
  Many angiotensin II type 1 receptor blockers (ARBs) are available for clinical use, but because they do not all have the same effects, the present study investigated whether all benefits conferred by ARBs are class effects.
  
  
  RESULTS
  Study 1 was a case-control study of patients with coronary artery disease, which showed that a non-depressor dose of valsartan significantly decreased the rate of target lesion revascularization at 6 months after stenting compared with the control group without ARB treatment. In Study 2, 44 patients with acute myocardial infarction who randomly received an initial lower dose of either valsartan or losartan after stenting were evaluated. The late loss and decrease in %diameter stenosis in the valsartan group were significantly lower than those in the losartan group as assessed by quantitative coronary angiography after 6 months. In addition, the valsartan group showed a significantly lower expression of intracellular adhesion molecule-1 and L-selectin.
  
  
  CONCLUSIONS
  A non-depressor dose of ARB may have beneficial effects on coronary restenosis that are associated with the regulation of adhesion molecules, and these effects might not be a class effect of ARBs.
authors.affiliation: Department of Cardiology, Fukuoka University School of Medicine.
authors.forename: Atsushi
authors.initials: A
authors.lastname: Iwata
authors.forename: Shin-ichiro
authors.initials: S
authors.lastname: Miura
authors.forename: Satoshi
authors.initials: S
authors.lastname: Imaizumi
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Kiya
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Nishikawa
authors.forename: Bo
authors.initials: B
authors.lastname: Zhang
authors.forename: Hideki
authors.initials: H
authors.lastname: Shimomura
authors.forename: Koichiro
authors.initials: K
authors.lastname: Kumagai
authors.forename: Kunihiro
authors.initials: K
authors.lastname: Matsuo
authors.forename: Kazuyuki
authors.initials: K
authors.lastname: Shirai
authors.forename: Keijiro
authors.initials: K
authors.lastname: Saku
mesh_terms: D000368:Aged; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D016022:Case-Control Studies; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D023903:Coronary Restenosis / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control; D023921:Coronary Stenosis / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D018799:Intercellular Adhesion Molecule-1 / Q000378:metabolism; D019041:L-Selectin / Q000378:metabolism; D019808:Losartan / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction; D013777:Tetrazoles / Q000627:therapeutic use*; D014633:Valine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000068756:Valsartan
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D013777:Tetrazoles; D018799:Intercellular Adhesion Molecule-1; D019041:L-Selectin; D000068756:Valsartan; D014633:Valine; D019808:Losartan